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Introduction
During the past few decades, gonadotropin-releasing
hormone (GnRH) analogs (GnRHa) have been widely
used for pituitary desensitization during controlled
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SUMMARY
Objective: Both gonadotropin-releasing hormone (GnRH) analogs and antagonists have been used for pitu-
itary desensitization during controlled ovarian hyperstimulation (COH). We aimed to determine the minimum
effective daily dose of GnRH antagonist in women undergoing COH. We also compared the efficiency of a
GnRH antagonist and a GnRH agonist.
Materials and Methods: Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo
transfer were divided into five groups: (1) cetrorelix 0.25 mg (n = 86); (2) cetrorelix 0.2 mg (n = 28); (3) cetrorelix
0.15 mg (n = 30); (4) leuprolide acetate (LA) 0.5 mg/day (n = 58); (5) single half-dose LA depot 1.88 mg
(n = 49). Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin
administration. LA or LA depot was started on day 21 of the previous menstrual cycle.
Results: We observed lower gonadotropin (Gn) dosages, estradiol (E2) levels and reduced risk of ovarian hyper-
stimulation syndrome (OHSS) in the GnRH antagonist groups. A higher risk of luteinizing hormone (LH) surge
was noted in cetrorelix 0.2 and 0.15 mg groups. Gn dosages (IU)/E2 levels (pg/mL) in each group were: (1) 1,949.4/
1,191.1; (2) 1,869.6/1,010.8; (3) 1,856.7/1,023.6; (4) 2,184.5/1,323.6; and (5) 2,103.5/1,313.5, respectively.
LH/OHSS risks were: (1) 3.5%/5.8%; (2) 7.1%/3.6%; (3) 13.3%/3.3%; (4) 3.4%/8.6%; and (5) 2%/8.2%, respectively.
Number of oocytes/embryos/grade I, II embryos were: (1) 9.4/7.9/5.8; (2) 7.5/4.2/3.6; (3) 6.3/4.1/3.1; (4) 12.3/
8.9/6.6; and (5) 11.8/8.4/6.1, respectively. There was no significant difference in terms of clinical outcomes between
groups 1, 4 and 5, except for higher abortion rates (AR) in group 1. Pregnancy rate (PR)/implantation rate (IR) ratios
in groups 1, 4, and 5 were statistically higher than those in groups 2 and 3. Chemical PR/IR/AR were: (1) 30.2%/
5.9%/7%; (2) 21.4%/5.1%/7.1%; (3) 16.7%/4.1%/10%; (4) 32.8%/5.5%/8.6%; and (5) 30.6%/5.7%/8.2%, respectively.
Conclusion: The lowest effective dosage of cetrorelix for pituitary desensitization during COH luteolysis is 0.25 mg,
resulting in a comparable PR but a higher AR when compared with GnRH agonist. [Taiwan J Obstet Gynecol 2008;
47(1):66–74]
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ovarian hyperstimulation (COH). The “long protocol”
with GnRHa is generally accepted for pituitary suppres-
sion, owing to its numerous advantages, including a
reduction in cancellation rates, the avoidance of prema-
ture luteinization and endogenous luteinizing hormone
(LH) surges, an increase in multiple follicular growth
[1] and potentially better timing of the treatment cycle
[2]. Traditionally, the short-acting GnRHa, leuprolide
acetate (LA), is widely used for pituitary suppression. LA
has been employed because of concerns over long-acting
depot preparations causing profound suppression and
luteal phase defects, which adversely affect pregnancy
and miscarriage rates [3]. However, the main advantage
of the long-acting GnRHa, LA depot, is its greater con-
venience, and its use is less stressful and more acceptable
than that of short-acting LA protocols. In a previous
report, we showed that single half-dose LA depot offered
a useful alternative for pituitary suppression in ovarian
stimulation during in vitro fertilization (IVF) [4].
GnRH antagonists (GnRH-ant) have been used to
prevent the onset of premature LH surges during COH.
The major disadvantages of GnRHa are increased gonad-
otropin (Gn) dosage after prolonged pituitary sup-
pression and a higher risk of ovarian hyperstimulation
syndrome (OHSS) [5]. GnRH-ant allow a short and
simple treatment regimen for IVF patients. GnRH-ant act
by competition with native GnRH for GnRH receptor-
binding sites, and result in rapid suppression of Gn.
Other advantages of GnRH-ant included the reduction
of Gn dosage during COH programs and a lower risk
of OHSS [6]. GnRH-ant greatly reduce the duration of
pituitary downregulation and prevent adverse events
related to flare-up induced by GnRHa.
The development of third- and fourth-generation
GnRH-ant has produced favorable clinical results.
Cetrorelix (ASTA-Medica, Frankfurt/Main, Germany) or
ganirelix (Organon, Oss, The Netherlands) have been
used in recent clinical studies [7,8]. Daily administra-
tion of GnRH-ant (so-called multiple dose protocol)
at its minimum effective dose (0.25 mg/day subcuta-
neously) has been proven to be safe and effective
[9,10]. Clinical studies using cetrorelix started off with
relatively high daily dosages of 3 mg and 1 mg [7,8], but
the lowest effective daily dose of cetrorelix appeared to
be 0.25 mg [11].
In reviewing the MEDLINE database, few studies
report trials of GnRH-ant in Asians. Hwang et al [12]
demonstrated that the cetrorelix-COH protocol had a
similar pregnancy rate (PR) as the GnRHa “long proto-
col” for women with polycystic ovary syndrome undergo-
ing IVF treatment. Recently, Lee et al [13] demonstrated
that both multiple and single dosage GnRH-ant proto-
cols were effective for preventing the LH surge, and
resulted in similar PR compared with LA GnRHa. They
also demonstrated that single dosage protocol required
further modification to produce favorable folliculoge-
nesis. However, no literature has dealt with the use of
GnRH-ant doses of 0.2 mg or less in pituitary suppres-
sion of thinner individuals. In general, Asian women are
thinner than Caucasian women. Given the racial and
ethnic differences, it is logical to suspect that Asians
and Caucasians might have different effective GnRH-
ant dosages.
To select a more efficient protocol for GnRH-ant
for IVF patients, we designed this randomized study 
to evaluate the follicular development and pregnancy
outcome using different dosage protocols for cetrore-
lix, LA and LA depot, as a GnRHa. In this larger series,
we aimed to determine the minimum safe and effective
dose of GnRH-ant for pituitary suppression in thin Asian
women and evaluated the effects of the different agents
on pituitary downregulation. Furthermore, we also com-
pared the clinical differences between GnRH-ant, LA,
and LA depot. Only a few studies [13–15] have com-
pared GnRH-ant and LA/LA depot. To our knowledge,
this is the largest survey and the first comparison of
these protocols in the Asian population.
Materials and Methods
All patients who received COH, IVF/intracytoplasmic
sperm injection (ICSI) and transvaginal embryo transfer
(TV-ET) were reviewed. This trial was a phase III, open-
label, randomized study to assess the efficacy and safety
of GnRH-ant in women undergoing COH. The main
inclusion criteria were: age at least 18 years but not older
than 39 years; and body weight of 40–70kg. Approval
from the institutional review board was obtained for
the analysis of this series.
The patients were divided into five groups: (1) cetro-
relix 0.25 mg/day (n = 86); (2) cetrorelix 0.2 mg/day
(n = 28); (3) cetrorelix 0.15 mg/day (n = 30); (4) LA
0.5 mg/day (n = 58); (5) LA depot 1.88 mg (n = 49).
Cetrorelix was administered from menstrual day 8 until
the day of human chorionic gonadotropin (hCG) admin-
istration. Single dose LA depot (1.88 mg, single subcu-
taneous dosage; Takeda Chemical Industries Ltd, Japan)
or daily LA (0.5 mg/day subcutaneously; Abbott Labo-
ratories, Chicago, IL, USA) were administered on days
21–23 of the previous menstrual cycle.
The COH protocol was as previously described [4].
In brief, during menstrual days 2–7, younger patients
(< 34 years) in the GnRH-ant/GnRHa groups were ad-
ministered 150–225 IU/day of recombinant follicle-
stimulating hormone (FSH) (Gonal-F; Serono, Rome,
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Italy). Older patients (≥ 34 years) in the GnRH-ant/
GnRHa groups were administered 225–300 IU/day of
Gonal-F. Ultrasound examinations were performed on
menstrual days 3, 6, 9, and 12. If the estradiol (E2)
level on day 8 was < 100 pg/mL, the daily dose of Gn
was increased to 225 IU of Gonal-F in younger patients
and to 300 IU of Gonal-F in the older patients. Criteria
for cancellation included lower E2 level on menstrual
day 8 (< 50 pg/mL) and poor follicle growth during
COH (no follicle growth > 8 mm).
The Gn cetrorelix or LA administration continued
until two or more follicles of ≥ 18 mm were detected;
then, hCG (5,000 IU; Serono, Rome, Italy) was adminis-
tered. Serum LH and E2 concentrations were tested on
the day of hCG administration. Oocytes were retrieved
transvaginally 34–36 hours later. Oocyte culture, insemi-
nation, embryo transfer (ET) and cryopreservation were
as previously described [4]. ET was performed 72 hours
after oocyte retrieval. A maximum of six embryos were
transferred in each patient. Luteal phase was supported
with hCG (2,000 IU/day; Serono, Rome, Italy) on days
1, 4 and 7 post-ET and progesterone (400 mg/day;
Utrogeston) from day 1 post-ET. Chemical pregnancy
was defined as elevated serum β-hCG (above 50 IU/L)
14 days after ET. Clinical pregnancy was determined
by visualization of a gestational sac, and fetal viability
by ultrasound 4 weeks post-ET.
Personal data (age, body weight, body mass index,
cause of infertility), Gn dosage, and serum concentra-
tion of LH and E2 on the day of hCG administration
were compared between the five groups. Serum E2, LH
and hCG levels were measured by means of immunoas-
say (Immulite 2000; DPC, Flanders, NJ, USA). Retrieved
oocyte and embryo numbers, development of OHSS,
embryo quality, and pregnancy rate (PR), implanta-
tion rate (IR) and abortion rate (AR) in each group
were assessed and compared. The SAS system version
8.1 (SAS Institute Inc., Cary, NC, USA) with ANOVA
test were used for statistical analysis. A p < 0.05 was
considered statistically significant.
Results
The mean ages, baseline FSH levels, and the indica-
tions for IVF treatment were comparable in each group
(Table 1). The body mass index in groups 2 and 3 were
lower, but not significantly, compared with groups 1,
4 and 5. Lower Gn dosages and E2 levels were noted in
the GnRH-ant groups when compared with the GnRHa
groups. Gn dosages (IU)/E2 levels (pg/mL) in each
group were: (1) 1,949.4/1,191.1; (2) 1,869.6/1,010.8;
(3) 1,856.7/1,023.6; (4) 2,184.5/1,323.6; and (5)
2,103.5/1,313.5, respectively (Tables 2 and 3). A higher
risk of LH surge was noted in the lower dosage groups
of GnRH-ant (cetrorelix 0.2 mg, 0.15 mg). OHSS risks
were lower in the GnRH-ant groups. LH/OHSS risks 
in each group were: (1) 3.5%/5.8%; (2) 7.1%/3.6%; (3)
13.3%/3.3%; (4) 3.4%/8.6%; and (5) 2%/8.2%, respec-
tively (Tables 2 and 3).
The number of oocytes retrieved/grade I, II embryos
in group 1 was higher than those in groups 2 and 3. The
0.25 mg cetrorelix group also produced better qualities
of embryos and oocytes. Number of oocytes/embryos/
grade I, II embryos in each group were: (1) 9.4/7.9/5.8;
(2) 7.5/4.2/3.6; (3) 6.3/4.1/3.1; (4) 12.3/8.9/6.6; and
(5) 11.8/8.4/6.1, respectively (Tables 2 and 3). We
observed a favorable outcome in the 0.25 mg cetrorelix
Table 1. Personal data for patients who received different dosages of gonadotropin-releasing hormone (GnRH) antagonist
(cetrorelix 0.25 mg, 0.2 mg, 0.25 mg), long- or short-acting form of GnRH agonists (leuprolide depot, leuprolide acetate)
for pituitary suppression during controlled ovarian hyperstimulation*
Cetrorelix 0.25 mg Cetrorelix 0.2 mg Cetrorelix 0.15 mg Leuprolide Leuprolide acetate
(n = 86) (n = 28) (n = 30) acetate (n = 58) depot (n = 49)
Age† (yr) 33.9 ± 4.4 32.3 ± 2.1 31.6 ± 2.4 30.9 ± 2.5 32.1 ± 2.7
BMI† (kg/m2) 20.6 ± 1.4 19.0 ± 1.0 19.5 ± 1.1 20.7 ± 2.1 21.1 ± 1.8
Baseline FSH levels† (IU/L) 4.0 ± 1.8 3.7 ± 1.6 3.9 ± 1.3 3.8 ± 1.4 3.6 ± 1.8
Infertility causes†
Tubal factor 28 (32.5) 8 (28.6) 7 (23.3) 16 (27.6) 13 (26.5)
Male factor 25 (29.1) 6 (21.4) 6 (20) 13 (22.4) 15 (30.6)
Endometriosis 11 (12.8) 5 (17.9) 4 (13.4) 6 (10.4) 10 (20.4)
Idiopathic 11 (12.8) 7 (25) 7 (23.3) 10 (17.2) 5 (10.2)
Others 11 (12.8) 2 (7.1) 6 (20) 13 (22.4) 6 (12.3)
*Data are presented as mean ± standard deviation or number (%); †non-significant difference. BMI = body mass index; FSH = follicle-stimulating hormone.
Taiwan J Obstet Gynecol • March 2008 • Vol 47 • No 1 69
GnRH Antagonist and GnRH Agonist in COH
group compared with the LA or LA depot groups. PR/IR
in groups 1, 4 and 5 were statistically higher than those
in groups 2 and 3. There were no significant differ-
ences in clinical outcomes between groups 1, 4 and 5,
except for higher ARs in the GnRH-ant groups. Chemical
PR/IR/AR in each group were: (1) 30.2%/5.9%/7%; 
(2) 21.4%/5.1%/7.1%; (3) 16.7%/4.1%/10%; (4) 32.8%/
5.5%/8.6%; and (5) 30.6%/5.7%/8.2%, respectively
(Tables 2 and 3).
Discussion
GnRHa have been used for pituitary suppression since
the mid-1980s to avoid the adverse effect of a prema-
ture LH surge [1,5]. In current practice, GnRHa are
routinely used to suppress endogenous Gn during IVF
treatment. The advantages of combining GnRHa with
a Gn in COH/IVF-ET using the “long protocol” have
been well known [16]. The use of a GnRHa for IVF
cycles significantly reduced the cycle cancellation rate
and improved the ovarian response [2,3]. Because psy-
chosocial stress may contribute to infertility [17], much
attention has been paid to simplifying the cycle program.
To overcome the stress and inconvenience induced 
by the daily administration of short-acting forms of
GnRHa, the use of long-acting GnRHa is practical and
reasonable. Gianaroli et al [18] have shown that when
the convenience, costs and side-effects are taken into
account, a single dose of long-acting GnRHa is prefer-
able. Albuquerque et al [19] demonstrated that LA
depot was associated with increased requirements for
Gn and a longer COH period, but similar PR, com-
pared with the LA protocol. In our previous study, we
Table 2. Clinical results and laboratory data for patients who received different dosages of gonadotropin-releasing hormone 
(GnRH) antagonist for pituitary suppression during controlled ovarian hyperstimulation*
Cetrorelix 0.25 mg Cetrorelix 0.2 mg Cetrorelix 0.15 mg
(n = 86) (n = 28) (n = 30)
GnRH antagonist dosage† (mg) 1.28 ± 0.29 1.07 ± 0.28 0.763 ± 0.147
Gonadotropin dosage‡ (IU) 1,949.4 ± 588.7 1,869.6 ± 409.3 1,856.7 ± 383.9
E2 on hCG day‡ (pg/mL) 1,191.1 ± 329.7 1,010.8 ± 259.1 1,023.6 ± 219.7
LH surge† 3 (3.5) 2 (7.1) 4 (13.3)
Ovarian hyperstimulation syndrome§ 5 (5.8) 1 (3.6) 1 (3.3)
Oocyte no.‡ 9.4 ± 5.54 7.5 ± 5.1 6.3 ± 6.7
Embryo no.‡ 7.9 ± 4.14 4.2 ± 2.2 4.1 ± 2.4
Grade I/II embryo no.‡ 5.8 ± 1.87 3.6 ± 2.2 3.1 ± 1.4
Chemical pregnancy rate† 26 (30.2) 6 (21.4) 5 (16.7)
Implantation rate‡ 5.9% 5.1% 4.1%
Abortion rate† 6 (7) 2 (7.1) 3 (10)
*Data are presented as mean ± standard deviation or number (%); †p < 0.05 between each group; ‡p < 0.05 between cetrorelix 0.25 mg and the other two
groups, non-significant difference between cetrorelix 0.2 mg and 0.15 mg groups; §non-significant difference between each group. E2 = estradiol; LH = luteinizing
hormone.
Table 3. Clinical results and laboratory data for patients who received long- or short-acting form of gonadotropin-releasing
hormone (GnRH) agonists for pituitary suppression during controlled ovarian hyperstimulation*
Cetrorelix 0.25 mg Leuprolide acetate Leuprolide acetate
(n = 86) (n = 58) depot (n = 49)
Gonadotropin dosage† (IU) 1,949.4 ± 588.7 2,184.5 ± 528.4 2,103.5 ± 486.4
E2 on hCG day† (pg/mL) 1,191.1 ± 329.7 1,323.6 ± 409.1 1,313.5 ± 427.7
LH surge‡ 3 (3.5) 2 (3.4) 1 (2)
Ovarian hyperstimulation syndrome† 5 (5.8) 5 (8.6) 4 (8.2)
Oocytes no.† 9.4 ± 5.54 12.3 ± 4.5 11.8 ± 5.1
Embryo no.† 7.9 ± 4.14 8.9 ± 2.7 8.4 ± 2.5
Grade I/II embryo no.† 5.8 ± 1.87 6.6 ± 2.3 6.1 ± 2.1
Chemical pregnancy rate‡ 26 (30.2) 19 (32.8) 15 (30.6)
Implantation rate‡ 5.9% 5.5% 5.7%
Abortion rate‡ 6 (7) 5 (8.6) 4 (8.2)
*Data are presented as mean ± standard deviation or number (%); †p < 0.05 between cetrorelix 0.25 mg and other two groups, non-significant difference between
LA and LA depot groups; ‡non-significant difference between each group. E2 = estradiol; LH = luteinizing hormone.
demonstrated that the use of low-dose LA depot had
the advantages of convenience, less stress and being
cost-effective [4].
The daily administration of short-acting GnRHa from
the luteal phase of the previous cycle by either injection
or intranasal spray is inconvenient, tiring and stressful.
However, the clinical effectiveness of long-acting forms
of GnRHa remains controversial. Long-acting GnRHa
appeared to shorten the pituitary desensitization, while
a longer duration of Gn stimulation and higher dosage
of Gn were necessary, compared with the short-acting
form [18,20]. Furthermore, the long-acting GnRHa
possibly impaired embryo development and implanta-
tion when compared with short-acting buserelin acetate
[3]. In contrast, some investigators have demonstrated
the advantage and clinical value of long-acting GnRHa.
Dhont et al [21] demonstrated that long-acting GnRHa
(goserelin) was reliable as an adjunct to follicular stim-
ulation in COH. Neuspiller et al [22] employed long-
acting GnRHa in ovum donation programs and observed
that long-acting forms of GnRHa provided similar suc-
cess rates and more convenient medication compared
with short-acting GnRHa. Dada et al [23] also demon-
strated that long-acting GnRHa were as effective as
short-acting analogs, with no detrimental effects on
the luteal phase.
Few investigators have studied the clinical effects of
lowering the dose of long-acting GnRHa. Simon et al
[24] reported that lowering the dose of LH-releasing
hormone (LHRH) analog to 0.1 mg/day during follicu-
logenesis had no adverse effect on the COH and IVF
results. Balasch et al [25] showed that the full dose
(3.75 mg) of D-Trp-6-LHRH depot and its half dose
(1.87 mg) were comparable in pituitary desensitization.
According to our past experiences, after the adjustment
of the LA depot dosage, we observed that half-dose LA
depot had similar effects on pituitary desensitization,
Gn dosage and PR, compared with the short-acting 
LA [16,26]. However, both LA and LA depot required
a rather long treatment period to achieve pituitary
downregulation and required the administration of
larger dosages of Gn to achieve adequate follicular
growth [16]. Higher Gn dosages, higher serum E2 on
the day of hCG administration, and multiple follicular
responses were identified as the major risk factors for
OHSS [17].
GnRH-ant have been developed in parallel with
GnRHa, but their development history has been plagued
by a high incidence of histamine release following injec-
tion. Over the past few years, progress in the preven-
tion of this histamine-releasing activity has been made.
Third-generation GnRH-ant (cetrorelix and ganirelix)
have been administered in a multiple dose regimen in
women undergoing COH. Until recently, GnRHa were
the only choice available to physicians for the preven-
tion of premature LH surges in women undergoing COH.
The recent approval of GnRH-ant for this indication
gives clinicians some new options. Major advantages
of GnRH-ant include a shorter duration of recruitment
and COH, reduced dosage of Gn, and a lower risk of
OHSS compared with GnRHa [13].
It is suggested that GnRHa have a direct effect on
ovarian steroidogenesis, which is independent of their
action on the pituitary [27]. This unwanted effect and
other possible drawbacks of GnRHa are thought to be
eliminated with the use of GnRH-ant. The mechanism
of action of GnRH-ant is through competitive blocking
of the GnRH receptor, which results in a rapid but
reversible suppression of Gn secretion. Because GnRH-
ant immediately suppress gonadotropins by blocking
GnRH receptors, treatment may be restricted to those
days when a premature LH surge is likely to occur. Serum
GnRH-ant concentrations increased in a linear dose-
proportional manner, while serum LH decreased in a
dose-proportional manner [28,29].
In several trials, the GnRH-ant regimens have been
associated with slightly lower PR and IR than the estab-
lished GnRHa protocols [30]. Although several studies
have indicated a slight reduction in PRs with GnRH-
ant, when compared with GnRHa, this problem may be
rectified by developing flexible regimens designed for
individual patients [31]. GnRH-ant can suppress the pre-
mature LH surge completely within a few hours, allow-
ing luteolysis by mid-cycle administration. Introducing
flexible GnRH-ant regimens aimed at improving clinical
outcomes should be an area for research in the near
future [32].
Two major protocols using GnRH-ant have been
developed, including a multiple dose (MD) regimen and
a single dose protocol (SD). In general, most investiga-
tors found more favorable results with the MD proto-
col than with the SD protocol [13]. The SD protocol
might result in greater suppression of serum LH than
the MD protocol [33]. The SD protocol was associ-
ated with a shorter duration of Gn use, smaller num-
bers of developing follicles, lower serum E2 levels on
the day of hCG administration, and a smaller number
of zygotes [13,34]. A fixed multi-dose GnRH-ant pro-
tocol is feasible for patients who are poor responders
to a long agonist protocol [32]. The maximum endo-
genous LH suppression occurs about 4 hours after
GnRH-ant administration [29]. Moreover, rapid recov-
ery of pituitary function was observed after discontin-
uation of GnRH-ant [35]. This was due to the relative
short elimination half-life (about 13hours) of GnRH-ant
[9]. These observations indicated that the degree of
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pituitary suppression could be adjusted by changing
the GnRH-ant dose according to the size of the leading
follicle. Starting the GnRH-ant according to the size of
the leading follicle (16mm) was as effective as starting on
a fixed day, and reduced GnRH-ant administration [36].
There is still controversy about the real efficacy of
GnRH-ant administration. Some investigators claimed
that an equivalent PR was achievable using GnRH-
ant protocols and GnRHa protocols [9,37–40]. Using
GnRH-ant may offer a favorable alternative for IVF
poor responder patients [41]. The GnRH-ant can pro-
vide short and simple treatment and are particularly
attractive for administration in women undergoing COH,
achieving comparable PR compared with the “long pro-
tocol” regimen. Zikopoulos et al [42] demonstrated
that GnRH-ant facilitated a short, simple treatment
and resulted in comparable PR when compared with
GnRHa in couples with unexplained infertility and/or
mild oligozoospermia and undergoing COH. Further-
more, GnRH-ant usage improved the PR in patients
with a history of multiple failures of IVF using a GnRHa
protocol, possibly because of improvement in the qual-
ity of the blastocysts generated [43]. Roulier et al [33]
compared SD cetrorelix (3 mg) and single full dosage
of GnRHa (Decapeptyl Retard 3.75 mg) in COH lute-
olysis, and found fewer recovered oocytes but similar
PR in the GnRH-ant group compared with the GnRHa
group.
In contrast, some investigators demonstrated lower
levels of serum E2, fewer small follicles/oocyte and
decreased PR in GnRH-ant cycles, when compared
with GnRHa [44–46]. The MD GnRH-ant protocol is a
short and simple protocol with a significant reduction
in incidence of OHSS but a lower PR compared with the
GnRHa long protocol [47]. GnRH-ant injection during
the early follicular phase would likely disturb the growth
of cohort follicles [48]. MD cetrorelix administration
might result in greater suppression of LH, which pro-
duces lower serum levels of E2 when Gn devoid of LH
are used [49]. Therefore, some LH supplement might
need to be considered during cetrorelix administration.
However, the addition of recombinant LH might pre-
vent a decrease in estradiol during GnRH-ant adminis-
tration, but does not positively influence the clinical
outcome in terms of oocyte number, maturation, embryo
quality, fertilization rate, PR, or IR [50].
Therefore, minimal dose adjustment of GnRH-ant
to suppress LH release without impairing the oocyte
development and embryo implantation might be con-
sidered in these situations. Concerning racial differ-
ences, most Asian women appeared to be thinner than
Caucasians. As 1.88 mg instead of 3.75 mg LA depot
has been proved to be an adequate dosage for pituitary
suppression in Asians [4,26], it is logical to suspect
this lower adjustment of cetrorelix dosage would also
apply for pituitary suppression in Taiwanese. To select
the minimum effective daily dose of GnRH-ant, a mul-
ticenter, double-blind, randomized, dose-finding study
was performed on 333 women, using six different
dosages ranging from 0.0625–2 mg [44,14]. Albano 
et al [10] demonstrated that the minimum effective
dose of cetrorelix able to prevent premature LH surge
in COH cycles was 0.25 mg/day in Caucasian individu-
als. A dose of 0.25 mg/day cetrorelix was considered
to be a safe, short and convenient treatment regimen
in women undergoing COH and resulted in a good
clinical outcome [44].
Borm and Mannaerts [9] demonstrated that a daily
dose of 0.25 mg GnRH-ant prevented an LH surge and
led to a favorable outcome (37% ongoing pregnancy
rate). LH is effective in stimulating E2 secretion in gran-
ulosa cells that have acquired LH-binding sites [51].
During COH, a relative elevation of serum LH level can
be observed, which might be suppressed immediately
by the GnRH-ant. The severe suppression by cetrorelix
might interrupt the folliculogenesis and decrease serum
E2 elevation. However, different GnRH-ant dosages
(cetrorelix 0.5 mg or 0.25 mg) have no different impact 
on the luteal phase of IVF/ICSI cycles when hormonal
support is given [10].
In women aged 40 years and older with abnormal
FSH levels, Weghofer et al [15] demonstrated that COH
with 0.25 mg of GnRH-ant resulted in favorable out-
comes. Escudero et al [52] demonstrated comparable
results with administration of GnRH-ant on different
days (administration on stimulation day 6 or when the
leading follicle was ≥ 14 mm). Engel et al [53] demon-
strated that body weight did not influence cetrorelix
plasma concentrations, and they, therefore, suggested
that cetrorelix modification was not necessary for indi-
viduals with different body weights treated with cetrore-
lix during COH. In contrast, Al-Inany and Aboulghar
[54] reported that serum levels of GnRH-ant exhibited
a linear inverse relationship to body weight, such that
it would seem likely that smaller women would pro-
bably require lower doses of GnRH-ant for preventing
the LH surge. A dose of 2.5 mg cetrorelix was effective
at achieving pregnancy in a clinical study in Taiwanese
women, and it was concluded that the difference could
be due to racial differences between Caucasian and
Asian women [55].
Despite the convenience of GnRH-ant application
during COH, the use of GnRH-ant rather than GnRHa
co-treatment for IVF is not widely accepted. One pos-
sible concern is that corpus luteum function seems to
be impaired in IVF cycles with GnRH-ant [56]. However,
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COH is associated with elevated progesterone levels in
the late follicular phase and accelerated endometrial
maturation in the subsequent luteal phase. Saadat et al
[57] demonstrated that non-significant differences in
pre-retrieval serial serum progesterone levels and luteal
phase endometrial histology existed between cycles uti-
lizing GnRHa or GnRH-ant. Luteal support is essential
when a long-acting GnRHa is used [58]. Adequate luteal
support compensates for luteolysis induced by GnRH-
ant and assures good clinical outcome. Herman et al
[58] have demonstrated that mid-luteal hCG addition
helped to preserve corpus luteum function. In our unit,
we routinely administer 2,500 IU of hCG on days 1, 4
and 7 post-ET, to prevent the negative effects of GnRHa
or GnRH-ant on the corpus luteum or the endometrium.
The reduced dose of long-acting GnRHa and the luteal
supplement of hCG may contribute to the similar luteal
desensitization and clinical results found with short-
acting GnRHa.
In this series, to the best of our knowledge, we have
demonstrated the largest application of MD cetrorelix
in Asians. We first tried a lower dosage of cetrorelix 
for Asians, but observed that the risk of an LH surge
was still high in the lower dosage groups (0.2 mg and
0.15 mg). The LH surge risk of 0.15–0.2 mg daily was
higher than that in 0.25 mg trials. We, therefore, con-
cluded that individuals with lower body weights (<50 kg)
still required a 0.25 mg daily dosage of cetrorelix. We
suggest that the 0.2 mg and 0.15 mg cetrorelix doses
are not suitable for LH suppression, even in the thinner
individuals.
We noted that PR/IR in the 0.25 mg group appeared
higher than in the 0.2 mg and 0.15 mg groups. The num-
ber of oocytes retrieved/grade I, II embryos was higher
in group 1 than in groups 2 and 3 (10.5/7.8 vs. 8.3/3.9).
A lower incidence of LH surge and higher E2 levels on
the day of hCG administration were observed in group
1 than in groups 2 and 3. There was a non-significant
difference between the 0.25 mg cetrorelix and the LA/
LA depot groups regarding prevention of an LH surge.
We observed non-statistical differences between cetrore-
lix groups (0.25 mg, 0.2 mg, 0.15 mg) in Gn dosage
and OHSS. The 0.25 mg cetrorelix resulted in similar
PR but higher AR compared with those of the LA/LA
depot groups [59]. The patients from the cetrorelix
group produced fewer follicles compared with individ-
uals from the LA/LA depot groups. The results might
be due to the absence of early pituitary downregulation
and synchronization of follicles during COH, lower Gn
dosage, as well as higher level of ovarian suppression
(reduced follicular development and depressed serum
E2 levels) and severe LH interruption during the later
folliculogenesis stages [13].
In conclusion, 0.25 mg of cetrorelix is the lowest
effective dosage for pituitary suppression during COH. 
A regimen of 0.25 mg MD cetrorelix showed comparable
pituitary suppression and clinical results with those of
LA/LA depot. Because of a higher risk of LH surge and
poorer clinical outcome, a lower dosage of cetrorelix
(0.2 mg, 0.15 mg) was unsuitable for pituitary suppres-
sion during COH. AR was still higher in 0.25 mg cetro-
relix administration. In view of the limited number of
patients studied, larger cohort recruitment is required
for further clarification. Furthermore, the influence of
GnRH-ant on the PR, synchronization of follicles, as
well as oocyte and embryo qualities, merits further study.
The real effect of cetrorelix upon the luteal phase also
merits further investigation. A bright future for the appli-
cation of GnRH-ant is expected. Further application of
GnH-ant will allow a short and simple treatment regi-
men for IVF patients undergoing COH, and it is expected
that the availability of GnRH-ant will lead to a shorter,
cheaper and safer protocol. Clinical outcomes may 
be improved by developing more flexible antagonist
regimens, an approach that requires further evaluation.
As clinicians gain experience with larger applications
of GnRH-ant, optimal treatment paradigms will likely
emerge.
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